



## Final Appraisal Recommendation

### Saxagliptin (Onglyza®)

Limited submission by:  
Bristol Myers Squibb/AstraZeneca EEIG

Advice No: 2011 – December 2011

### Recommendation of AWMSG

Saxagliptin (Onglyza®) is recommended as an option for use within NHS Wales as an add-on combination therapy for use in adult patients with type 2 diabetes mellitus with moderate or severe renal impairment to improve glycaemic control.

AWMSG is of the opinion that saxagliptin (Onglyza®) may be suitable for shared care within NHS Wales.

#### Additional notes:

This recommendation applies only to the use of Saxagliptin (Onglyza®) for the indication under consideration.

Saxagliptin (Onglyza®) for the above indication met the following criteria for eligibility for a limited submission:

- Minor licence extension
- Anticipated usage in NHS Wales is considered to be of minimal budgetary impact.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: